Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Oruka Therapeutics, Inc stake
total: 670
Viking Global Investors ORKA trades
- Total transactions:
- 2
- New positions:
- 1
- Reduced:
- 1
- Held since:
- 2025 Q3
- Held for:
- 4 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Ole Andreas Halvorsen holds 1,503,478 Oruka Therapeutics, Inc (ORKA) shares with a market value of roughly $143.09M accounting for 0.41% of the overall portfolio. To date, the estimated cost basis is nearly $19.23 for "buy" trades and estimated average "sell" price is $95.17. Viking Global Investors first purchased ORKA in 2025 Q3, initially acquiring about 2.67M shares. Since the initial investment in Oruka Therapeutics, Inc (ORKA), Viking Global Investors has made 1 more transaction.
When did Ole Andreas Halvorsen buy Oruka Therapeutics, Inc (ORKA)?
Ole Andreas Halvorsen first invested in Oruka Therapeutics, Inc (ORKA) in 2025 Q3 at the reported quarter-end price of $19.23 per share.
What's the cost basis of Viking Global Investors's ORKA stake?
The estimated cost basis for Oruka Therapeutics, Inc (ORKA) stake is around $19.23 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $19.23
- Weighted AVG sell price:
- $95.17
Ole Andreas Halvorsen's historical trades in Oruka Therapeutics, Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.41%
|
1,503,478
|
$95.17
|
$143,086,001
|
-43.62% (-1,163,212)
|
-0.31%
|
|
2025 Q3
|
0.13%
|
2,666,690
|
$19.23
|
$51,280,449
|
new
|
+0.13%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.